Research programme: neurodegenerative disorders therapeutics - FORUM PharmaceuticalsAlternative Names: EVP-0002442; EVP-2442; Neurodegenerative disorders therapeutics - EnVivo
Latest Information Update: 10 Apr 2014
At a glance
- Originator EnVivo Pharmaceuticals
- Developer CHDI; EnVivo Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurodegenerative disorders
Most Recent Events
- 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
- 13 Feb 2008 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
- 30 Nov 2005 Preclinical trials in Neurodegenerative disorders in USA (unspecified route)